In re application of: Hitoshi Fujimiya et al.	)	Docket Number: Y03S013-US	
Serial No.: 10/761885	)		
Filed: January 21, 2004	)	Group art Unit:	Not known
FOR: COMPUTER SOFTWARE PROGRAM FOR GRAPHICALLY DISPLAYING GENETIC LINKAGE UNBALANCES. AND THE METHOD THEREOF	) ) )		

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Information Disclosure Statement

## Dear Sir:

Enclosed is a copy of the Information Disclosure Citation Form together with copies of the documents cited on that form. It is respectfully requested that the cited. documents be considered and that the enclosed copy of the Information Disclosure Citation Form be initialed by the Examiner to indicate such consideration and a copy thereof returned to applicant(s).

Pursuant to 37 C.F.R. § 1.97(g) and (h), the submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed as an admission that the information cited in this statement is material to patentability.

The following is the translation of the underlined section in the Japanese reference (TOYO KITAMURA, Logic of Linkage Disequilibrium, Genetic Statistics in the post genome era, Oct. 10, 2001, Page 183-201, Kabushikigaisha Yodosha, Tokyo, Japan):

"D' is considered to have optimal characteristics as a scale, because it depends only on the genetic distance between a marker and a disease gene locus."

Pursuant to 37 C.F.R. § 1.97, this Information Disclosure Statement is being submitted under one of the following (as indicated by an "X" to the left of the appropriate paragraph):

A certification pursuant to 37 C.F.R. §1.97(e) or	 •	If so, then enclosed with this Information Disclosure		
<del></del>	 Statement is <u>one</u> of the following:  A certification pursuant to 37 C.F.R. §1.97(e) or			
	 Tree Parameter	3 1 3 1 5 7 (0) <u>0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 </u>		

 A check for	§ for the fee under 37 C,F.R. § 1.17(p).
37 C.F.R. §	1.97(d). If so, then enclosed with this Information Disclosure
State	ment are the following:
(1)	A certification pursuant to 37 C.F.R. §1.97(e)*;
(2)	A petition requesting consideration of the Information Disclosure Statement; and
(3)	A check for \$ for the fee under 37 C.F.R. §1.17(p)
( )	for submission of the Information Disclosure Statement.
was	t each item of information contained in the Information Disclosure Statement cited in a communication from a foreign patent office in a counterpart ign application not more than three months prior to filing this statement.
or, t	t no item of information contained in the information statement was cited in a munication from a foreign patent office in a counterpart foreign application to the knowledge of the undersigned attorney after making reasonable inquiry, known to any individual designated in 1.56(c) more than three months prior aling of this statement.
If there are a	ny additional charges, please charge Deposit Account No. 502270.

Should the Examiner have any questions or comments regarding the Information Disclosure Statement, the Examiner is invited to telephone the undersigned at the number listed below.

Date: May 7, 2004

Respectfully submitted,

Konomi Takeshita Registration No. 38,333

Omori & Yaguchi USA, LLC

Agent for Applicant

Eight Penn Center, Suite 1901

1628 John F. Kennedy Blvd.

Philadelphia, PA 19103

Phone No. (215) 701-6349

AUG 2 0 2004 33

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
LLS Patent and Trademark Office: LLS DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Agricia Res, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1445/1 TO	Application Number	10/761885	
INFORMATION DISCLOSURE	Filing Date	January 21, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Hitoshi Fujimiya	
(Use as many sheets as necessary)	Art Unit	Not Known	
(Ose as many sneets as necessary)	Examiner Name	Not Known	
Sheet 1 of 1	Attorney Docket Number	Y03S013-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		JURG OTT, Analysis of Human Genetic Linkage, DATE?, Page 280-296, The Johns Hopkins University Press, Baltimore, US	
		TIANHUA NIU, ZHAOHUI S. QIN, XIPING XU, and JUN S. LIU, Bayesian Haplotype Inference for Multiple Linked Single-Nucloptide Polymorphisms, The American Journal of Human Genetics 70, Page 157-169, 2002, The University of Chicago Press, Chicago, IL	
		TOYO KITAMURA, Logic of Linkage Disequilibrium, Genetic Statistics in the post genome era, Oct. 10, 2001, Page 183-201, Kabushikigaisha Yodosha, Tokyo, Japan	
		KENNETH P. BURNHAM, and DAVID R. ANDERSON, Model Selection and Multimodel Inference, Page 60-97, 2002, Springer-Verlag New York, Inc., US	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.